{"nctId":"NCT00450658","briefTitle":"Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated Ulcers","startDateStruct":{"date":"2007-03"},"conditions":["Peptic Ulcer"],"count":627,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: HZT-501"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ibuprofen"]}],"interventions":[{"name":"HZT-501","otherNames":[]},{"name":"Ibuprofen","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Expected to require daily administration of a nonsteroidal anti-inflammatory drug (NSAID) for at least the coming six months for conditions such as osteoarthritis, rheumatoid arthritis, chronic low back pain, chronic regional pain syndrome, and chronic soft tissue pain.\n* Did not use a NSAID within the 30 days prior to study entry\n\nExclusion Criteria:\n\n* History of erosive esophagitis\n* History of any of the following serious gastrointestinal complications:\n\n  * perforation of ulcers,\n  * gastric outlet obstruction due to ulcers,\n  * gastrointestinal bleeding.\n* Active cardiac, renal, and/or hepatic disease\n* Current Helicobacter pylori (H. pylori) infection\n* Use of an acid suppressant agent, misoprostol, or more than 325 mg/day of aspirin within the 14 days prior to study entry.\n* Uncontrolled diabetes\n* Uncontrolled hypertension\n* Positive pregnancy test at screening\n* Positive test at Screening for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.\n* Currently participating, or participation within 30 days prior to study entry, in an investigational drug study\n\nPlease note that there are other additional criteria. The study center will determine if patients meet all of the criteria.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects Who Develop Endoscopically-diagnosed Upper Gastrointestinal Ulcers Confirmed by Endoscopy.","description":"The primary efficacy endpoint was the number of subjects with upper gastrointestinal (i.e., gastric and/or duodenal) ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A subject is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Who Develop Endoscopically-diagnosed Gastric Ulcers During the 24-week Treatment Period.","description":"The secondary efficacy endpoint was the number of subjects with gastric ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A subject is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Who Develop Endoscopically-diagnosed Duodenal Ulcers During the 24-week Treatment Period.","description":"The secondary efficacy endpoint was the number of subjects with duodenal ulcer at any time throughout the 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A subject is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"The Incidence Rate of NSAID-associated Serious Gastrointestinal Complications.","description":"The secondary efficacy endpoint was the number of subjects developing a NSAID-associated serious GI complication at any time throughout 6 months of treatment. A NSAID-associated serious GI complication was defined as a perforation of ulcers, gastric outlet obstruction due to ulcers, and/or GI bleeding.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":415},"commonTop":["dyspepsia","nausea","upper respiratory tract infection","diarrhea","constipation"]}}}